ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump
Objective: To characterize the local safety and PK of a novel apomorphine formulation, ND0701, in comparison to a commercially available apomorphine–HCl solution. Background: Apomorphine is…Osteopathic manipulative treatment in Parkinson’s disease: Preliminary results of a double blind sham-controlled cross-over study
Objective: The primary objective of this study is to quantitatively evaluate the effect of osteopathic manipulative treatment (OMT) in Parkinson's disease. Background: Patients with Parkinson's…Use of nicotine gum to treat acute low blood pressure in Parkinson’s disease
Objective: To evaluate (1) how nicotine chewing gum is tolerated (2) how nicotine chewing gum affects acute low blood pressure (BP) in Parkinson's disease (PD).…Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease
Objective: The aim of this study was to characterize the levodopa and carbidopa plasma concentration in relation to blinded motor function ratings. This is a…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry
Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA
Objective: The primary endpoint of clinical progression is measured by change in the total UPDRS score between baseline and 1) after 52 weeks of study…Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany
Objective: To evaluate the duration of treatment (DOT) and safety of apomorphine continuous subcutaneous infusion (CSI) in patients with advanced PD inscribed in a managed…Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature
Objective: To examine the histology of subcutaneous nodules after continuous subcutaneous apomorphine infusion (CSAI). Background: CSAI has been used successfully in advanced Parkinson's disease (PD).…Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study
Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study
Objective: To analyze the long-term retrospective data of patients treated with Levodopa/carbidopa intestinal gel infusion (LCIG) and subthalamic nucleus deep brain stimulation (STN-DBS) in two…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.